PMV Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
400 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540
Mailing Address
400 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540
Phone
(609) 642-6670
Fiscal Year End
1231
EIN
463218129
Financial Overview
FY2025
$15.21M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 10-K Annual financial report | March 6, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 4, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
Annual Reports
10-K
March 6, 2026
- Developing rezatapopt (PPM-001) to restore p53 function, a critical tumor suppressor, for cancer treatment.
- Pursuing an accelerated approval path for a tumor-agnostic indication, aiming to treat various solid tumors with specific p53 mutations.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.